PT2549983E - Nova composiçao para o tratamento de trombocitemia essencial - Google Patents

Nova composiçao para o tratamento de trombocitemia essencial Download PDF

Info

Publication number
PT2549983E
PT2549983E PT117102020T PT11710202T PT2549983E PT 2549983 E PT2549983 E PT 2549983E PT 117102020 T PT117102020 T PT 117102020T PT 11710202 T PT11710202 T PT 11710202T PT 2549983 E PT2549983 E PT 2549983E
Authority
PT
Portugal
Prior art keywords
treatment
novel composition
essential thrombocythemia
thrombocythemia
essential
Prior art date
Application number
PT117102020T
Other languages
English (en)
Inventor
Adam Wax
John W Pyhtila
Original Assignee
Aop Orphan Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42732455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2549983(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aop Orphan Pharmaceuticals Ag filed Critical Aop Orphan Pharmaceuticals Ag
Publication of PT2549983E publication Critical patent/PT2549983E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Paints Or Removers (AREA)
PT117102020T 2010-03-25 2011-03-25 Nova composiçao para o tratamento de trombocitemia essencial PT2549983E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10157772 2010-03-25

Publications (1)

Publication Number Publication Date
PT2549983E true PT2549983E (pt) 2015-06-17

Family

ID=42732455

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117102020T PT2549983E (pt) 2010-03-25 2011-03-25 Nova composiçao para o tratamento de trombocitemia essencial

Country Status (23)

Country Link
US (4) US20130028945A1 (pt)
EP (1) EP2549983B1 (pt)
JP (1) JP5836357B2 (pt)
AU (1) AU2011231557B2 (pt)
BR (1) BR112012024239A2 (pt)
CA (1) CA2794237C (pt)
CY (1) CY1116396T1 (pt)
DK (1) DK2549983T3 (pt)
EA (1) EA027576B1 (pt)
ES (1) ES2535480T3 (pt)
HR (1) HRP20150410T1 (pt)
IL (1) IL222072A (pt)
ME (1) ME02118B (pt)
MX (1) MX2012011051A (pt)
NZ (1) NZ602366A (pt)
PL (1) PL2549983T3 (pt)
PT (1) PT2549983E (pt)
RS (1) RS53960B1 (pt)
SG (1) SG184227A1 (pt)
SI (1) SI2549983T1 (pt)
SM (1) SMT201500119B (pt)
UA (1) UA110933C2 (pt)
WO (1) WO2011117391A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011231557B2 (en) * 2010-03-25 2016-05-26 Aop Orphan Pharmaceuticals Ag Novel composition for treatment of essential thrombocythemia
CN112675178A (zh) * 2014-12-22 2021-04-20 速达制药有限公司 预防和治疗血小板增多的癌症患者中的转移性疾病
EP4183430A1 (en) 2021-11-18 2023-05-24 Koninklijke Philips N.V. Sensor arrangement for a breast pump device and breast pump device using the sensor arrangement

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
AU2003231777C1 (en) * 2002-04-29 2009-10-29 Supernus Pharmaceuticals, Inc. Pharmaceutical formulations with improved bioavailability
US7993654B2 (en) * 2002-12-23 2011-08-09 Beiersdorf Ag Self-adhesive polymer matrix containing sea algae extract
EP1744750A2 (en) * 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
EP2114380A1 (en) * 2007-01-25 2009-11-11 Panacea Biotec Ltd. Modified release pharmaceutical composition and a process of making the same
GB2460915B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
AT10562U3 (de) * 2008-12-05 2010-01-15 Aop Orphan Pharmaceuticals Ag Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytämie
US8465770B2 (en) * 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
AU2011231557B2 (en) * 2010-03-25 2016-05-26 Aop Orphan Pharmaceuticals Ag Novel composition for treatment of essential thrombocythemia

Also Published As

Publication number Publication date
PL2549983T3 (pl) 2015-08-31
US20180028538A1 (en) 2018-02-01
EP2549983A2 (en) 2013-01-30
SG184227A1 (en) 2012-10-30
EA201201329A1 (ru) 2013-02-28
WO2011117391A3 (en) 2012-01-19
EP2549983B1 (en) 2015-03-04
NZ602366A (en) 2014-08-29
MX2012011051A (es) 2013-01-29
HRP20150410T1 (hr) 2015-06-05
SMT201500119B (it) 2015-07-09
CA2794237C (en) 2017-09-26
US9782413B2 (en) 2017-10-10
AU2011231557A1 (en) 2012-10-04
RS53960B1 (sr) 2015-08-31
JP2013523616A (ja) 2013-06-17
US20150086637A1 (en) 2015-03-26
ES2535480T3 (es) 2015-05-12
SI2549983T1 (sl) 2015-06-30
US20170035768A1 (en) 2017-02-09
UA110933C2 (uk) 2016-03-10
ME02118B (me) 2015-10-20
EA027576B1 (ru) 2017-08-31
IL222072A (en) 2017-12-31
JP5836357B2 (ja) 2015-12-24
CA2794237A1 (en) 2011-09-29
AU2011231557B2 (en) 2016-05-26
US20130028945A1 (en) 2013-01-31
CY1116396T1 (el) 2017-02-08
DK2549983T3 (da) 2015-06-01
BR112012024239A2 (pt) 2016-07-12
WO2011117391A2 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
IL229830B (en) Novel compinds as modulatord of gpr-119
ZA201304280B (en) Treatment of jak2-mediated conditions
PL2609120T3 (pl) Ulepszony sposób wytwarzania sugammadeksu
PT3023788T (pt) Composições de neoantigénios específicos de tumor para utilização no tratamento de tumores
IL222199A0 (en) Process for preparation of dopo-derived compounds and compositions thereof
EP2771030A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES
IL256026B (en) Treatment methods
IL224381B (en) Application of b-functionalized dihydroxy-chlorins for pdt
ZA201208389B (en) Treatment of proliferative diseases
PL2651251T3 (pl) Kompozycja do leczenia bezpłodności
IL213198A0 (en) Novel composition for treatment of essential thrombocythemia
IL222072A (en) Composition for the treatment of primary thrombocythemia
PL2460509T3 (pl) Kompozycja do leczenia brodawek
PT2603319E (pt) Processo para a preparação de uretanos
IL222903A0 (en) Composition of small molecule therapeutices
EP2537851A4 (en) PROCESS FOR PREPARING B-GLYCOSIDE COMPOUNDS
ZA201409502B (en) Composition for treatment of warts
GB201010638D0 (en) Composition for treatment of skin
GB201012310D0 (en) Composition for the treatment of botulism
HU1000688D0 (en) Use of trifluoro-phal